http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 09 Feb 2026 01:00:15 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/FDA/Peijia+Medical+submits+EU+regulatory+application+for+heart+device/25963648.html <p>Peijia Medical Limited (HKEX: 9996) submitted a European Union Medical Device Regulation CE Mark registration application for its GeminiOne Transcatheter Edge-to-Edge Repair system, the Hong Kong-based company announced. The device treats mitral regurgitation through a minimally invasive cardiac procedure.</p> <p>The GeminiOne system features a sliding groove mechanism designed to enable longer coaptation length while maintaining a smaller implant size. The device includes an independent leaflet grasping design, an auto-locking mechanism, and multi-angular detachment capability to accommodate various anatomical variations.</p> <p>HighLife SAS serves as the company's European partner for the regulatory submission process. The system has received patents globally and has undergone multiple http://www.streetinsider.com/FDA/Peijia+Medical+submits+EU+regulatory+application+for+heart+device/25963648.html Mon, 09 Feb 2026 01:00:15 -0500 9996 A.06822034 O.20026344 O.28513020 http://www.streetinsider.com/FDA/Peijia+Medical+submits+EU+regulatory+application+for+heart+device/25963648.html <p>Peijia Medical Limited (HKEX: 9996) submitted a European Union Medical Device Regulation CE Mark registration application for its GeminiOne Transcatheter Edge-to-Edge Repair system, the Hong Kong-based company announced. The device treats mitral regurgitation through a minimally invasive cardiac procedure.</p> <p>The GeminiOne system features a sliding groove mechanism designed to enable longer coaptation length while maintaining a smaller implant size. The device includes an independent leaflet grasping design, an auto-locking mechanism, and multi-angular detachment capability to accommodate various anatomical variations.</p> <p>HighLife SAS serves as the company's European partner for the regulatory submission process. The system has received patents globally and has undergone multiple http://www.streetinsider.com/FDA/Peijia+Medical+submits+EU+regulatory+application+for+heart+device/25963648.html Mon, 09 Feb 2026 01:00:15 -0500 9996 A.06822034 O.20026344 O.28513020 http://www.streetinsider.com/FDA/Peijia+Medical+submits+EU+regulatory+application+for+heart+device/25963648.html <p>Peijia Medical Limited (HKEX: 9996) submitted a European Union Medical Device Regulation CE Mark registration application for its GeminiOne Transcatheter Edge-to-Edge Repair system, the Hong Kong-based company announced. The device treats mitral regurgitation through a minimally invasive cardiac procedure.</p> <p>The GeminiOne system features a sliding groove mechanism designed to enable longer coaptation length while maintaining a smaller implant size. The device includes an independent leaflet grasping design, an auto-locking mechanism, and multi-angular detachment capability to accommodate various anatomical variations.</p> <p>HighLife SAS serves as the company's European partner for the regulatory submission process. The system has received patents globally and has undergone multiple http://www.streetinsider.com/FDA/Peijia+Medical+submits+EU+regulatory+application+for+heart+device/25963648.html Mon, 09 Feb 2026 01:00:15 -0500 9996 A.06822034 O.20026344 O.28513020 http://www.streetinsider.com/FDA/Peijia+Medical+submits+EU+regulatory+application+for+heart+device/25963648.html <p>Peijia Medical Limited (HKEX: 9996) submitted a European Union Medical Device Regulation CE Mark registration application for its GeminiOne Transcatheter Edge-to-Edge Repair system, the Hong Kong-based company announced. The device treats mitral regurgitation through a minimally invasive cardiac procedure.</p> <p>The GeminiOne system features a sliding groove mechanism designed to enable longer coaptation length while maintaining a smaller implant size. The device includes an independent leaflet grasping design, an auto-locking mechanism, and multi-angular detachment capability to accommodate various anatomical variations.</p> <p>HighLife SAS serves as the company's European partner for the regulatory submission process. The system has received patents globally and has undergone multiple http://www.streetinsider.com/FDA/Peijia+Medical+submits+EU+regulatory+application+for+heart+device/25963648.html Mon, 09 Feb 2026 01:00:15 -0500 9996 A.06822034 O.20026344 O.28513020 http://www.streetinsider.com/Press+Releases/Peijia+Medical+Submits+EU+MDR+CE+Mark+Registration+Application+for+GeminiOne%C2%AE+TEER+System/25963645.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LC/hk" idsrc="xmltag.org" >HONG KONG</location></span>, <span class="legendSpanClass"><chron>Feb. 9, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:9996" idsrc="xmltag.org" >Peijia Medical Limited</span> (HKEX: 9996) today announced that it has formally submitted the European Union Medical Device Regulation (EU MDR) CE Mark registration application for its internally developed <b>GeminiOne Transcatheter Edge-to-Edge Repair (TEER) System</b> for the treatment of mitral regurgitation, with HighLife SAS being the Company's European partner.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Peijia+Medical+Submits+EU+MDR+CE+Mark+Registration+Application+for+GeminiOne%C2%AE+TEER+System/25963645.html Mon, 09 Feb 2026 01:00:00 -0500 9996 A.06822034 O.20026344 O.28513020 http://www.streetinsider.com/Press+Releases/Peijia+Medical+Submits+EU+MDR+CE+Mark+Registration+Application+for+GeminiOne%C2%AE+TEER+System/25963645.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LC/hk" idsrc="xmltag.org" >HONG KONG</location></span>, <span class="legendSpanClass"><chron>Feb. 9, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:9996" idsrc="xmltag.org" >Peijia Medical Limited</span> (HKEX: 9996) today announced that it has formally submitted the European Union Medical Device Regulation (EU MDR) CE Mark registration application for its internally developed <b>GeminiOne Transcatheter Edge-to-Edge Repair (TEER) System</b> for the treatment of mitral regurgitation, with HighLife SAS being the Company's European partner.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Peijia+Medical+Submits+EU+MDR+CE+Mark+Registration+Application+for+GeminiOne%C2%AE+TEER+System/25963645.html Mon, 09 Feb 2026 01:00:00 -0500 9996 A.06822034 O.20026344 O.28513020 http://www.streetinsider.com/Press+Releases/Peijia+Medical+Submits+EU+MDR+CE+Mark+Registration+Application+for+GeminiOne%C2%AE+TEER+System/25963645.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LC/hk" idsrc="xmltag.org" >HONG KONG</location></span>, <span class="legendSpanClass"><chron>Feb. 9, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:9996" idsrc="xmltag.org" >Peijia Medical Limited</span> (HKEX: 9996) today announced that it has formally submitted the European Union Medical Device Regulation (EU MDR) CE Mark registration application for its internally developed <b>GeminiOne Transcatheter Edge-to-Edge Repair (TEER) System</b> for the treatment of mitral regurgitation, with HighLife SAS being the Company's European partner.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Peijia+Medical+Submits+EU+MDR+CE+Mark+Registration+Application+for+GeminiOne%C2%AE+TEER+System/25963645.html Mon, 09 Feb 2026 01:00:00 -0500 9996 A.06822034 O.20026344 O.28513020 http://www.streetinsider.com/Press+Releases/Peijia+Medical+Submits+EU+MDR+CE+Mark+Registration+Application+for+GeminiOne%C2%AE+TEER+System/25963645.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LC/hk" idsrc="xmltag.org" >HONG KONG</location></span>, <span class="legendSpanClass"><chron>Feb. 9, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:9996" idsrc="xmltag.org" >Peijia Medical Limited</span> (HKEX: 9996) today announced that it has formally submitted the European Union Medical Device Regulation (EU MDR) CE Mark registration application for its internally developed <b>GeminiOne Transcatheter Edge-to-Edge Repair (TEER) System</b> for the treatment of mitral regurgitation, with HighLife SAS being the Company's European partner.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Peijia+Medical+Submits+EU+MDR+CE+Mark+Registration+Application+for+GeminiOne%C2%AE+TEER+System/25963645.html Mon, 09 Feb 2026 01:00:00 -0500 9996 A.06822034 O.20026344 O.28513020 http://www.streetinsider.com/PRNewswire/Peijia+Medical+Submits+EU+MDR+CE+Mark+Registration+Application+for+GeminiOne%C2%AE+TEER+System/25963645.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LC/hk" idsrc="xmltag.org" >HONG KONG</location></span>, <span class="legendSpanClass"><chron>Feb. 9, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:9996" idsrc="xmltag.org" >Peijia Medical Limited</span> (HKEX: 9996) today announced that it has formally submitted the European Union Medical Device Regulation (EU MDR) CE Mark registration application for its internally developed <b>GeminiOne Transcatheter Edge-to-Edge Repair (TEER) System</b> for the treatment of mitral regurgitation, with HighLife SAS being the Company's European partner.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Peijia+Medical+Submits+EU+MDR+CE+Mark+Registration+Application+for+GeminiOne%C2%AE+TEER+System/25963645.html Mon, 09 Feb 2026 01:00:00 -0500 9996 A.06822034 O.20026344 O.28513020 http://www.streetinsider.com/PRNewswire/Peijia+Medical+Submits+EU+MDR+CE+Mark+Registration+Application+for+GeminiOne%C2%AE+TEER+System/25963645.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LC/hk" idsrc="xmltag.org" >HONG KONG</location></span>, <span class="legendSpanClass"><chron>Feb. 9, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:9996" idsrc="xmltag.org" >Peijia Medical Limited</span> (HKEX: 9996) today announced that it has formally submitted the European Union Medical Device Regulation (EU MDR) CE Mark registration application for its internally developed <b>GeminiOne Transcatheter Edge-to-Edge Repair (TEER) System</b> for the treatment of mitral regurgitation, with HighLife SAS being the Company's European partner.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Peijia+Medical+Submits+EU+MDR+CE+Mark+Registration+Application+for+GeminiOne%C2%AE+TEER+System/25963645.html Mon, 09 Feb 2026 01:00:00 -0500 9996 A.06822034 O.20026344 O.28513020 http://www.streetinsider.com/PRNewswire/Peijia+Medical+Submits+EU+MDR+CE+Mark+Registration+Application+for+GeminiOne%C2%AE+TEER+System/25963645.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LC/hk" idsrc="xmltag.org" >HONG KONG</location></span>, <span class="legendSpanClass"><chron>Feb. 9, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:9996" idsrc="xmltag.org" >Peijia Medical Limited</span> (HKEX: 9996) today announced that it has formally submitted the European Union Medical Device Regulation (EU MDR) CE Mark registration application for its internally developed <b>GeminiOne Transcatheter Edge-to-Edge Repair (TEER) System</b> for the treatment of mitral regurgitation, with HighLife SAS being the Company's European partner.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Peijia+Medical+Submits+EU+MDR+CE+Mark+Registration+Application+for+GeminiOne%C2%AE+TEER+System/25963645.html Mon, 09 Feb 2026 01:00:00 -0500 9996 A.06822034 O.20026344 O.28513020 http://www.streetinsider.com/PRNewswire/Peijia+Medical+Submits+EU+MDR+CE+Mark+Registration+Application+for+GeminiOne%C2%AE+TEER+System/25963645.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LC/hk" idsrc="xmltag.org" >HONG KONG</location></span>, <span class="legendSpanClass"><chron>Feb. 9, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:9996" idsrc="xmltag.org" >Peijia Medical Limited</span> (HKEX: 9996) today announced that it has formally submitted the European Union Medical Device Regulation (EU MDR) CE Mark registration application for its internally developed <b>GeminiOne Transcatheter Edge-to-Edge Repair (TEER) System</b> for the treatment of mitral regurgitation, with HighLife SAS being the Company's European partner.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Peijia+Medical+Submits+EU+MDR+CE+Mark+Registration+Application+for+GeminiOne%C2%AE+TEER+System/25963645.html Mon, 09 Feb 2026 01:00:00 -0500 9996 A.06822034 O.20026344 O.28513020 http://www.streetinsider.com/Press+Releases/Peijia+Medical+Receives+NMPA+Approval+for+TaurusTrio+Transcatheter+Aortic+Valve+System%2C+Pioneering+Treatment+for+Aortic+Regurgitation+in+China/25732281.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LC/hk" idsrc="xmltag.org" >HONG KONG</location></span>, <span class="legendSpanClass"><chron>Dec. 12, 2025</chron></span> /PRNewswire/ -- Peijia Medical (9996.HK), a leading Chinese domestic company in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, announced that its TaurusTrio Transcatheter Aortic Valve (TAV) system received approval from the <span>National Medical Products Administration</span> (NMPA) of <location value="LC/cn" idsrc="xmltag.org" >China</location> on <chron>December 11, 2025</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Peijia+Medical+Receives+NMPA+Approval+for+TaurusTrio+Transcatheter+Aortic+Valve+System%2C+Pioneering+Treatment+for+Aortic+Regurgitation+in+China/25732281.html Fri, 12 Dec 2025 07:30:00 -0500 9996 A.30912197 A.60012012 O.16504837 O.20847516 O.28513020 http://www.streetinsider.com/Press+Releases/Peijia+Medical+Receives+NMPA+Approval+for+TaurusTrio+Transcatheter+Aortic+Valve+System%2C+Pioneering+Treatment+for+Aortic+Regurgitation+in+China/25732281.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LC/hk" idsrc="xmltag.org" >HONG KONG</location></span>, <span class="legendSpanClass"><chron>Dec. 12, 2025</chron></span> /PRNewswire/ -- Peijia Medical (9996.HK), a leading Chinese domestic company in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, announced that its TaurusTrio Transcatheter Aortic Valve (TAV) system received approval from the <span>National Medical Products Administration</span> (NMPA) of <location value="LC/cn" idsrc="xmltag.org" >China</location> on <chron>December 11, 2025</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Peijia+Medical+Receives+NMPA+Approval+for+TaurusTrio+Transcatheter+Aortic+Valve+System%2C+Pioneering+Treatment+for+Aortic+Regurgitation+in+China/25732281.html Fri, 12 Dec 2025 07:30:00 -0500 9996 A.30912197 A.60012012 O.16504837 O.20847516 O.28513020 http://www.streetinsider.com/Press+Releases/Peijia+Medical+Receives+NMPA+Approval+for+TaurusTrio+Transcatheter+Aortic+Valve+System%2C+Pioneering+Treatment+for+Aortic+Regurgitation+in+China/25732281.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LC/hk" idsrc="xmltag.org" >HONG KONG</location></span>, <span class="legendSpanClass"><chron>Dec. 12, 2025</chron></span> /PRNewswire/ -- Peijia Medical (9996.HK), a leading Chinese domestic company in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, announced that its TaurusTrio Transcatheter Aortic Valve (TAV) system received approval from the <span>National Medical Products Administration</span> (NMPA) of <location value="LC/cn" idsrc="xmltag.org" >China</location> on <chron>December 11, 2025</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Peijia+Medical+Receives+NMPA+Approval+for+TaurusTrio+Transcatheter+Aortic+Valve+System%2C+Pioneering+Treatment+for+Aortic+Regurgitation+in+China/25732281.html Fri, 12 Dec 2025 07:30:00 -0500 9996 A.30912197 A.60012012 O.16504837 O.20847516 O.28513020 http://www.streetinsider.com/Press+Releases/Peijia+Medical+Receives+NMPA+Approval+for+TaurusTrio+Transcatheter+Aortic+Valve+System%2C+Pioneering+Treatment+for+Aortic+Regurgitation+in+China/25732281.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LC/hk" idsrc="xmltag.org" >HONG KONG</location></span>, <span class="legendSpanClass"><chron>Dec. 12, 2025</chron></span> /PRNewswire/ -- Peijia Medical (9996.HK), a leading Chinese domestic company in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, announced that its TaurusTrio Transcatheter Aortic Valve (TAV) system received approval from the <span>National Medical Products Administration</span> (NMPA) of <location value="LC/cn" idsrc="xmltag.org" >China</location> on <chron>December 11, 2025</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Peijia+Medical+Receives+NMPA+Approval+for+TaurusTrio+Transcatheter+Aortic+Valve+System%2C+Pioneering+Treatment+for+Aortic+Regurgitation+in+China/25732281.html Fri, 12 Dec 2025 07:30:00 -0500 9996 A.30912197 A.60012012 O.16504837 O.20847516 O.28513020 http://www.streetinsider.com/Press+Releases/Peijia+Medical+Receives+NMPA+Approval+for+TaurusTrio+Transcatheter+Aortic+Valve+System%2C+Pioneering+Treatment+for+Aortic+Regurgitation+in+China/25732281.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LC/hk" idsrc="xmltag.org" >HONG KONG</location></span>, <span class="legendSpanClass"><chron>Dec. 12, 2025</chron></span> /PRNewswire/ -- Peijia Medical (9996.HK), a leading Chinese domestic company in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, announced that its TaurusTrio Transcatheter Aortic Valve (TAV) system received approval from the <span>National Medical Products Administration</span> (NMPA) of <location value="LC/cn" idsrc="xmltag.org" >China</location> on <chron>December 11, 2025</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Peijia+Medical+Receives+NMPA+Approval+for+TaurusTrio+Transcatheter+Aortic+Valve+System%2C+Pioneering+Treatment+for+Aortic+Regurgitation+in+China/25732281.html Fri, 12 Dec 2025 07:30:00 -0500 9996 A.30912197 A.60012012 O.16504837 O.20847516 O.28513020 http://www.streetinsider.com/Press+Releases/Peijia+Medical+Receives+NMPA+Approval+for+TaurusTrio+Transcatheter+Aortic+Valve+System%2C+Pioneering+Treatment+for+Aortic+Regurgitation+in+China/25732281.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LC/hk" idsrc="xmltag.org" >HONG KONG</location></span>, <span class="legendSpanClass"><chron>Dec. 12, 2025</chron></span> /PRNewswire/ -- Peijia Medical (9996.HK), a leading Chinese domestic company in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, announced that its TaurusTrio Transcatheter Aortic Valve (TAV) system received approval from the <span>National Medical Products Administration</span> (NMPA) of <location value="LC/cn" idsrc="xmltag.org" >China</location> on <chron>December 11, 2025</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Peijia+Medical+Receives+NMPA+Approval+for+TaurusTrio+Transcatheter+Aortic+Valve+System%2C+Pioneering+Treatment+for+Aortic+Regurgitation+in+China/25732281.html Fri, 12 Dec 2025 07:30:00 -0500 9996 A.30912197 A.60012012 O.16504837 O.20847516 O.28513020 http://www.streetinsider.com/PRNewswire/Peijia+Medical+Receives+NMPA+Approval+for+TaurusTrio+Transcatheter+Aortic+Valve+System%2C+Pioneering+Treatment+for+Aortic+Regurgitation+in+China/25732281.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LC/hk" idsrc="xmltag.org" >HONG KONG</location></span>, <span class="legendSpanClass"><chron>Dec. 12, 2025</chron></span> /PRNewswire/ -- Peijia Medical (9996.HK), a leading Chinese domestic company in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, announced that its TaurusTrio Transcatheter Aortic Valve (TAV) system received approval from the <span>National Medical Products Administration</span> (NMPA) of <location value="LC/cn" idsrc="xmltag.org" >China</location> on <chron>December 11, 2025</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Peijia+Medical+Receives+NMPA+Approval+for+TaurusTrio+Transcatheter+Aortic+Valve+System%2C+Pioneering+Treatment+for+Aortic+Regurgitation+in+China/25732281.html Fri, 12 Dec 2025 07:30:00 -0500 9996 A.30912197 A.60012012 O.16504837 O.20847516 O.28513020 http://www.streetinsider.com/PRNewswire/Peijia+Medical+Receives+NMPA+Approval+for+TaurusTrio+Transcatheter+Aortic+Valve+System%2C+Pioneering+Treatment+for+Aortic+Regurgitation+in+China/25732281.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LC/hk" idsrc="xmltag.org" >HONG KONG</location></span>, <span class="legendSpanClass"><chron>Dec. 12, 2025</chron></span> /PRNewswire/ -- Peijia Medical (9996.HK), a leading Chinese domestic company in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, announced that its TaurusTrio Transcatheter Aortic Valve (TAV) system received approval from the <span>National Medical Products Administration</span> (NMPA) of <location value="LC/cn" idsrc="xmltag.org" >China</location> on <chron>December 11, 2025</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Peijia+Medical+Receives+NMPA+Approval+for+TaurusTrio+Transcatheter+Aortic+Valve+System%2C+Pioneering+Treatment+for+Aortic+Regurgitation+in+China/25732281.html Fri, 12 Dec 2025 07:30:00 -0500 9996 A.30912197 A.60012012 O.16504837 O.20847516 O.28513020 http://www.streetinsider.com/PRNewswire/Peijia+Medical+Receives+NMPA+Approval+for+TaurusTrio+Transcatheter+Aortic+Valve+System%2C+Pioneering+Treatment+for+Aortic+Regurgitation+in+China/25732281.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LC/hk" idsrc="xmltag.org" >HONG KONG</location></span>, <span class="legendSpanClass"><chron>Dec. 12, 2025</chron></span> /PRNewswire/ -- Peijia Medical (9996.HK), a leading Chinese domestic company in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, announced that its TaurusTrio Transcatheter Aortic Valve (TAV) system received approval from the <span>National Medical Products Administration</span> (NMPA) of <location value="LC/cn" idsrc="xmltag.org" >China</location> on <chron>December 11, 2025</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Peijia+Medical+Receives+NMPA+Approval+for+TaurusTrio+Transcatheter+Aortic+Valve+System%2C+Pioneering+Treatment+for+Aortic+Regurgitation+in+China/25732281.html Fri, 12 Dec 2025 07:30:00 -0500 9996 A.30912197 A.60012012 O.16504837 O.20847516 O.28513020 http://www.streetinsider.com/PRNewswire/Peijia+Medical+Receives+NMPA+Approval+for+TaurusTrio+Transcatheter+Aortic+Valve+System%2C+Pioneering+Treatment+for+Aortic+Regurgitation+in+China/25732281.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LC/hk" idsrc="xmltag.org" >HONG KONG</location></span>, <span class="legendSpanClass"><chron>Dec. 12, 2025</chron></span> /PRNewswire/ -- Peijia Medical (9996.HK), a leading Chinese domestic company in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, announced that its TaurusTrio Transcatheter Aortic Valve (TAV) system received approval from the <span>National Medical Products Administration</span> (NMPA) of <location value="LC/cn" idsrc="xmltag.org" >China</location> on <chron>December 11, 2025</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Peijia+Medical+Receives+NMPA+Approval+for+TaurusTrio+Transcatheter+Aortic+Valve+System%2C+Pioneering+Treatment+for+Aortic+Regurgitation+in+China/25732281.html Fri, 12 Dec 2025 07:30:00 -0500 9996 A.30912197 A.60012012 O.16504837 O.20847516 O.28513020 http://www.streetinsider.com/PRNewswire/Peijia+Medical+Receives+NMPA+Approval+for+TaurusTrio+Transcatheter+Aortic+Valve+System%2C+Pioneering+Treatment+for+Aortic+Regurgitation+in+China/25732281.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LC/hk" idsrc="xmltag.org" >HONG KONG</location></span>, <span class="legendSpanClass"><chron>Dec. 12, 2025</chron></span> /PRNewswire/ -- Peijia Medical (9996.HK), a leading Chinese domestic company in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, announced that its TaurusTrio Transcatheter Aortic Valve (TAV) system received approval from the <span>National Medical Products Administration</span> (NMPA) of <location value="LC/cn" idsrc="xmltag.org" >China</location> on <chron>December 11, 2025</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Peijia+Medical+Receives+NMPA+Approval+for+TaurusTrio+Transcatheter+Aortic+Valve+System%2C+Pioneering+Treatment+for+Aortic+Regurgitation+in+China/25732281.html Fri, 12 Dec 2025 07:30:00 -0500 9996 A.30912197 A.60012012 O.16504837 O.20847516 O.28513020 http://www.streetinsider.com/PRNewswire/Peijia+Medical+Receives+NMPA+Approval+for+TaurusTrio+Transcatheter+Aortic+Valve+System%2C+Pioneering+Treatment+for+Aortic+Regurgitation+in+China/25732281.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LC/hk" idsrc="xmltag.org" >HONG KONG</location></span>, <span class="legendSpanClass"><chron>Dec. 12, 2025</chron></span> /PRNewswire/ -- Peijia Medical (9996.HK), a leading Chinese domestic company in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, announced that its TaurusTrio Transcatheter Aortic Valve (TAV) system received approval from the <span>National Medical Products Administration</span> (NMPA) of <location value="LC/cn" idsrc="xmltag.org" >China</location> on <chron>December 11, 2025</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Peijia+Medical+Receives+NMPA+Approval+for+TaurusTrio+Transcatheter+Aortic+Valve+System%2C+Pioneering+Treatment+for+Aortic+Regurgitation+in+China/25732281.html Fri, 12 Dec 2025 07:30:00 -0500 9996 A.30912197 A.60012012 O.16504837 O.20847516 O.28513020 http://www.streetinsider.com/Press+Releases/Peijia+Medical+Announces+2025+Interim+Results/25243932.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LC/hk" idsrc="xmltag.org" >HONG KONG</location></span>, <span class="legendSpanClass"><chron>Aug. 25, 2025</chron></span> /PRNewswire/ -- <span value="HongKong:9996" idsrc="xmltag.org" >Peijia Medical</span> (9996.HK), a leading Chinese domestic player in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, announced financial results for the six months ended <chron>June 30, 2025</chron> ("the Reporting Period") on <chron>August 22, 2025</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> <a target="_blank" href="https://mma.prnewswire.com/media/2166853/PEIJIA_Logo_Logo.html" http://www.streetinsider.com/Press+Releases/Peijia+Medical+Announces+2025+Interim+Results/25243932.html Mon, 25 Aug 2025 08:00:00 -0500 9996 O.28513020